Bardin Hill Management Partners LP Acquires New Stake in Catalent, Inc. (NYSE:CTLT)

Bardin Hill Management Partners LP bought a new position in Catalent, Inc. (NYSE:CTLT) during the third quarter, HoldingsChannel.com reports. The fund bought 170,380 shares of the company’s stock, valued at approximately $10,320,000. Catalent accounts for 4.8% of Bardin Hill Management Partners LP’s portfolio, making the stock its 6th biggest position.

Several other institutional investors and hedge funds have also made changes to their positions in CTLT. Millennium Management LLC increased its stake in Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after buying an additional 2,299,784 shares during the period. Bank of Montreal Can grew its stake in Catalent by 181.5% in the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after acquiring an additional 1,169,044 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Catalent by 166.5% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock worth $83,733,000 after acquiring an additional 863,624 shares during the period. ING Groep NV raised its stake in shares of Catalent by 162.5% during the third quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock valued at $68,475,000 after acquiring an additional 699,851 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Catalent in the third quarter valued at approximately $39,082,000.

Insiders Place Their Bets

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by insiders.

Catalent Price Performance

Shares of CTLT stock opened at $61.11 on Monday. The stock’s 50-day moving average is $59.90 and its 200 day moving average is $58.51. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $61.50. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The company has a market cap of $11.09 billion, a P/E ratio of -27.04, a PEG ratio of 2.43 and a beta of 1.16.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.10) earnings per share. Research analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on CTLT shares. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, StockNews.com lowered shares of Catalent from a “hold” rating to a “sell” rating in a report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.